Clinical Trials Results
|
Results for the search you initiated will be displayed below.
-
Click here for details...
This phase II trial tests whether nivolumab in combination with cabozantinib works in
patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab,
may help the body's immune system attack the cancer, and may interfere with the ability of
tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. It works by blocking the action of an abnormal
protein that signals tumor cells to multiply. This helps stop the spread of tumor cells.
Giving nivolumab in combination with cabozantinib could prevent cancer from returning.
-
Click here for details...
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given
together with or without sargramostim and to see how well they work in treating patients with
stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with
monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system
attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Colony-stimulating factors, such as sargramostim, may increase the production of white blood
cells. It is not yet known whether nivolumab and ipilimumab are more effective with or
without sargramostim in treating patients with melanoma.
-
Click here for details...
This phase II trial studies how well encorafenib and binimetinib work before surgery in
treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph
nodes. Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. This trial also studies how well 18F-FLT positron emission
tomography (PET)/computed tomography (CT) works in predicting the response of melanoma to
encorafenib and binimetinib. 18F-FLT is an imaging agent, sometimes called a tracer. PET and
CT are types of imaging scans. Using 18F-FLT PET/CT together with encorafenib and binimetinib
may provide more information on melanoma over time.
-
Click here for details...
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus
ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread
to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are
monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread.
This trial aims to find out which approach is more effective in shrinking and controlling
brain metastases from melanoma.
|
